Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CGRA.....nope
$CGRA...Imagine that....be good to see a base of $.10 the upward
$SSBN.....$.70 entry looking good and $1.50 add just as good..
$TNIB...
from PR Statement.
PR Newswire TNI BioTech, Inc.
July 14, 2014 3:17 PM
"Cytocom, Inc., has received interest from two investment banking firms to underwrite and fund Cytocom pursuant to a S-1 Registration Statement that would fund the company's development plan.
"Upon the spin-off, Cytocom will be able to focus on its development stage, targeted immunology and oncology pipeline and once spin-off and distribution is complete, Cytocom will operate as a stand-alone publicly traded company," said Dr. Graham Burton President and CEO of Cytocom."
$QUES....looking forward to third and fourth quarter growth IMO
amen
Those who are patient and those who are acquiring down here are going to do very good IMO and those that hold and don't sell right away on any big movement are going to do even better iMO
Good things will come to those that wait IMO
$SIBE...I think your on the wrong board here. This is a real company with a real business and will be $dollars in the near future IMO.
$QUES....You are soo smart
$TNIB...good things...
$QUES....Big...BIGger....BIGGEST.....
$CGRA...no the point is that the company is finally looking and becoming real. Funding will help growth and growth should eventually reflect in PPS and when PPS grows so will investors pockets IMO.
$QUES...agree 10000%....
$CGRA...please keep selling stock down here....and for that matter please sell on the way up at .02 and .04 as well.....and when its $.10....will hold for even more after that...
$TNIB...actually you can't sue. As far as I know tnib is not dtc eligible. Which is why you must send In your certs to "PROVE" what you have in TNIB and be held till divi date so you can't just sell before divi and still get divi. AND the "company" actually makes the rules on the dividend, how its paid and what investors need to do to receive it. You the investor don't get to decide what you will or won't do. You do however get to decide NOT to receive the divi and NOT to follow instructions to receive the divi. Then by NOT following the instructions laid out by the company to receive the divi you will have zero grounds for any recourse against the company for not getting divi IMO of course.
$QUES obviously you can't read. I don't recall the word "only" in any part of my post.... :-0
$QUES....Double the pleasure...Double the fun...yum yum
$CGRA...people with SHORT attention spans will never make BIG money. Looks like the company is starting to become real from this point on.... Good for "investors" IMO
$SIBE could easily be $1.00 to $3.00 next year IMO
$TNIB....back to $1.00 range in the near future IMO...Cytocom....$2...$5...$100.00....IMO of course.
$CGRA....
$QUES...$3.00 min by first Quarter next year IMO...who knows maybe more. Maybe much more...
$QUES.....could end up being MASSIVE....who knows....imo
$CGRA...finally looking a bit more stable....looks like it might get back to the .04 range soon.
$TNIB...why not....lots of good changes coming forward...A new name with a new focus seems great gong forward...
$SSBN.....looking good
$SIBE...strong buy long hold...imo
$QUES
$TNIB
$QUES...amen
$TNIB..NEWES..TNI BioTech Inc. Announces First Shipment of Lodonal® to The Republic of Panama and The Republic of Malawi
PR Newswire TNI BioTech, Inc.
1 hour ago
ORLANDO, Fla, Aug. 27, 2014 /PRNewswire/ -- TNI BioTech Inc. (TNIB), ("we" or the "Company") a biotechnology company pioneering the manufacturing and marketing of innovative therapies for autoimmune diseases in emerging nations, today announced it had received payment and will make its first shipments of Lodonal® to the Republic of Panama and The Republic of Malawi in conjunction with our marketing partner, The Brewer Group, Inc.
Commenting on the initial shipments, Noreen Griffin, CEO of TNI BioTech, stated, "Extensive work has been conducted and funds spent over the last twelve months obtaining local regulatory approval preparing for the launch of Lodonal® in these markets including participation at health conferences, drug dossiers, clinical case studies and training for sales professionals. We are confident that our distributors and sales teams are well positioned to establish Lodonal® as a major competitor in the treatment of cancer and autoimmune diseases in emerging nations. We are looking forward to launching Lodonal® in additional markets in the fourth quarter of 2014."
Lodonal® is an active immunotherapy with low dose naltrexone (LDN), an oral medication that works by activating a patient's immune system against HIV/AIDS and tumor cells or by rebalancing the immune system of patients with autoimmune diseases with no toxic side effects.
Lodonal® competes in the advanced cancer and autoimmune drug market. Global Industry Analysis, Inc. recently released a comprehensive global report on the Autoimmune Disease Therapeutics market, which stated that the global market for Autoimmune Disease Therapeutics is projected to exceed US$77 billion by the year 2017, driven by the rising incidence of autoimmune complications worldwide. We believe that Lodonal® has demonstrated potential clinical and economic advantages over existing treatments for a number of chronic and acute autoimmune diseases, such as HIV/AIDS, certain cancers, rheumatoid arthritis, multiple sclerosis, Crohn's Disease and inflammatory bowel disease.
TNIB previously announced the launch of Lodonal® sales through PanAm Global Logistics, Inc. in conjunction with The Brewer Group, Inc. to the Republic of Malawi, Africa. "We are very excited to work with PanAm to begin distributing Lodonal® in Africa," stated His Excellency Ambassador Jack Brewer, founder and CEO of The Brewer Group. "The Brewer Group strives to serve a global vision with a social focus through all our advisory work and this opportunity to spread awareness for Lodonal® in emerging markets exemplifies the power of our mission. We will immediately save lives by providing access to a trusted and affordable therapy to those living in the poorest areas in the world who are suffering from cancer and other autoimmune diseases."
In June 2014, TNIB announced the signing of a distribution agreement for the non-exclusive distribution of Lodonal® into Malawi, Panama, Sri Lanka, Egypt, Malaysia and Haiti. With this sale, TNIB, through it is wholly owned subsidiary Airmed Biopharma Limited, will begin monthly shipments under the existing agreement. TNIB anticipates revenue of $1,800,000 dollars over the next twelve months.
"We're very happy with the relationship that we've created with both PanAm Global Logistics, Inc and The Brewer Group, as this is an important step in implementing our international marketing and distribution program," said Noreen Griffin, CEO of TNI BioTech.
About TNI BioTech, Inc.
TNI BioTech is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin ("MENK") (sometimes referred to as opioid growth factor ("OGF")) and our Low Dose Naltrexone product ("LDN") or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
About Airmed Biopharma Limited
Airmed Biopharma Limited, a wholly owned Irish company, is the pharmaceutical sales division of TNI BioTech. Airmed is responsible for servicing sales orders for Lodonal® in countries where TNI BioTech has received sales approval.
About Cytocom, Inc.
Cytocom, Inc. is a biotechnology company that will initially focus on developing Low Dose Naltrexone (Lodonal®) and met-enkephalin in the investigation of unmet medical needs in the areas of oncological and inflammatory diseases.
About The Brewer Group, Inc.
Established in 2005, The Brewer Group is a multi-faceted global investment advisory firm focused on providing tailored services including capital markets, asset management, specialty finance and business development for public and private companies as well as high-profile clientele including athletes, entertainers and world leaders. TBG specializes in multiple sectors including: financial services; biotechnology & healthcare; sports; media & entertainment; wearable technology & consumer products; sustainable technology & agriculture; education & cultural exchange; and hospitality. The Brewer Group's relationships with high-profile clientele and affiliates including United Nations representatives, global organizations, distribution outlets, governments, key government and non-governmental officials, NPOs, agencies and unions as well as with various public and private corporations and international organizations place TBG in a unique position to execute a wide range of services around the globe. Additionally, The Brewer Group supports a 501(c)(3) non-profit organization, The Jack Brewer Foundation (JBF Worldwide), which uses its various programs and global initiatives to offer educational opportunities and economic development to underprivileged individuals around the world and its Chief Executive Officer, Jack Brewer, also serves as an Ambassador for Peace and Sport for the US Federation of Middle East Peace (USFMEP) at the United Nations. For further information, please visit www.thebrewergroup.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release and the statements of representatives and partners of the Company related thereto include various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" used in the Company's press releases and in the Company's filings with the Securities and Exchange Commission as well as Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve assumptions and significant risks and uncertainties. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release, and thus readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
For further information, please see http://www.tnibiotech.com
Contact: Dennis S. Dobson, 203-258-0159
$QUES...NEWS...entering into $17 Billion Dollar Aviation inspection industry.
Quest Solution, Inc. Enters Aviation Safety Industry through Acquisition of Airframe Inspection Technology
New technology added to portfolio of intangibles in the company
Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Henderson, NV (PRWEB) August 27, 2014
Quest Solution, Inc, "The Company" (OTCBB: QUES), is pleased to announce under an irrevocable, perpetual and exclusive worldwide right and license, the acquisition of an Airframe Inspection system for commercial and military aircraft. The license, acquired from Rampart Detection Systems, will be held in the Company’s recently formed Intellectual Property Division which has announced gun safety and mining technology additions as well.
“Aviation Week estimates the Aircraft and Maintenance business is a $17.5 billion industry. We expect that selling this service on a savings basis will yield tremendous growth,” stated Kurt Thomet, President, Quest Solution, Inc. “Quest Solution possesses the reputation and leadership in our core company verticals as well as specific leadership in our new Intellectual Property division to pursue this enormous market opportunity.”
“Mr. Augie Sick, who recently joined our Board, will oversee the introduction of this dynamic technology in the commercial marketplace,” added Jason Griffith, CEO of Quest Solution, Inc. “I am greatly pleased by our recent acquisitions under our IP banner and that we have the specific management team to ensure a success. It takes both.”
Highlights of the Air Frame inspection system are:
Patent Pending Exclusive Technology incorporates a novel form of electrodynamic imaging, along with proprietary signal processing algorithms which employ rugged, highly sensitive sensors optimized for secure reliable service.
Aircraft are required by the FAA (Federal Aeronautics Association) to be C level and D level inspected at certain hours of operation. C Level inspections require up to 6,000 man hours and D level inspections require up to 50,000 hours and cost as much as $ 1M. These inspections are currently performed using X-Ray Technology which requires much disassembly of the aircraft to accomplish and take aircraft out of operation for weeks.
The System under this license is expected to reduce costs by as much as $250,000 to $500,000 per aircraft because of lower labor costs, faster inspections and more efficient overall inspection procedures.
This mobile solution has been tested on Sikorsky Helicopters with results that support the superior performance and time saving capabilities.
The Company is currently working towards obtaining strategic partners to establish pilot projects and take the solution out of the lab and into production.
About Rampart Detection Systems Rampart Detection Systems is a Canadian based research and development company with international patents on EMRAC, FEPS, and VariLuc. They have been delivering solutions for decades. http://www.RampartDetection.com
For more information http://www.QuestSolution.com
About Quest Solution, Inc.:
Quest Solution, Inc. is a leading provider in the technology, software, and mobile data collection systems business. The Company intends on continuing to acquire existing companies with revenues and positive cash flow.
Quest Solution, Inc. serves as a national mobility systems integrator with a focus on design, delivery, deployment and support of fully integrated mobile solutions. The Company takes a consultative approach by offering end to end solutions that include hardware, software, communications and full lifecycle management services. The highly tenured team of professionals simplifies the integration process and delivers proven problem solving solutions backed by numerous customer references.
Additionally we recently announced the creation of a wholly-owned division focused on commercializing Intellectual Property, Patents and Distribution of industry-specific technologies in an array of new verticals. The new division will focus on acquisition of existing intangibles which will provide immediate value to the company.
Information about Forward-Looking Statements
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for Quest Solution, Inc's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in Quest Solution Inc.'s filings with the United States Securities and Exchange Commission. Examples of such forward looking statements in this release include statements regarding growth in our parts and vehicle sales and increases in our ability to produce new products. For a more detailed description of the risk factors and uncertainties affecting Quest Solution, Inc. please refer to the Company's recent Securities and Exchange Commission filings, which are available at http://www.sec.gov. Quest Solution, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Quest Solution, Inc. Investor Relations & Financial Media:
I.M.I.
888-216-3595
info(at)integrityir.com
$QUES
$SSBN .